Alexion Pharma (ALXN) Tops Q1 EPS by 18c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Pharmaceuticals (ALXN) PT Raised to $155 at Stifel
April 26, 2018 4:50 PM EDTStifel raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $155.00 (from $151.00) while maintaining a Buy rating.
Analyst Stephen Willey comments "The near-miss on statistical superiority with ALXN1210 (vs. Soliris) in the P3 Switch trial should also improve sentiment around the ability of... More
Alexion Pharma (ALXN) Reports Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
April 26, 2018 7:51 AM EDTAlexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today is also announcing positive topline results of a Phase 3 study of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, which show that patients with paroxysmal nocturnal hemoglobinuria (PNH) can be effectively and safely switched from treatment with Soliris® (eculizumab) every two weeks to treatment with ALXN1210 every eight weeks. The study demonstrated non-inferiority of ALXN1210 to Soliris® in patients with PNH who had been stable on Soliris® based on the primary endpoint of change in lactate dehydrogenase (LDH) levels, a direct marker of complement-mediated hemolysis in PNH. The study... More
